Last 7 days
Bookmark and Share    
Full Text
Peer Reviewed
See detailInternational Osteoporosis Foundation and European Calcified Tissue Society working group. Recommendations for the screening of the adherence to oral bisphosphonates.
DIEZ-PEREZ, A; NAYLOR, K.E.; ABRAHAMSEN, B et al

in Osteoporosis International (2017), 28(3), 767-774

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the ... [more ▼]

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug. Introduction: Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients. Methods: The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis. Results: Based on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and CTX at baseline and 3 months after starting therapy to check for a decrease above the least significant change (decrease of more than 38% for PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one is considered when measuring both, the level of detection is 94.5%. Conclusions: If a significant decrease is observed, the treatment can continue, but if no decrease occurs, the clinician should reassess to identify problems with the treatment, mainly low adherence. [less ▲]

Detailed reference viewed: 11 (4 ULg)
Full Text
Peer Reviewed
See detailPublic Health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France.
HILIGSMANN, M.; BURLET, N.; FARDELLONE, P. et al

in Osteoporosis International (2017), 28(3), 833-840

Summary: The recommended intake of vitamin D-fortified dairy products can substantially decrease the burden of osteoporotic fractures and seems an economically beneficial strategy in the general French ... [more ▼]

Summary: The recommended intake of vitamin D-fortified dairy products can substantially decrease the burden of osteoporotic fractures and seems an economically beneficial strategy in the general French population aged over 60 years. Introduction: This study aims to assess the public health and economic impact of vitamin D-fortified dairy products in the general French population aged over 60 years. Methods: We estimated the lifetime health impacts expressed in number of fractures prevented, life years gained, and quality-adjusted life years (QALY) gained of the recommended intake of dairy products in the general French population over 60 years for 1 year (2015). A validated microsimulation model was used to simulate three age cohorts for both women and men (60–69, 70–79, and >80 years). The incremental cost per QALY gained of vitamin D-fortified dairy products compared to the absence of appropriate intake was estimated in different populations, assuming the cost of two dairy products per day in base case. Results: The total lifetime number of fractures decreased by 64,932 for the recommended intake of dairy products in the general population over 60 years, of which 46,472 and 18,460 occurred in women and men, respectively. In particular, 15,087 and 4413 hip fractures could be prevented in women and men. Vitamin D-fortified dairy products also resulted in 32,569 QALYs and 29,169 life years gained. The cost per QALY gained of appropriate dairy intake was estimated at €58,244 and fall below a threshold of €30,000 per QALY gained in women over 70 years and in men over 80 years. Conclusion: Vitamin D-fortified dairy products have the potential to substantially reduce the burden of osteoporotic fractures in France and seem an economically beneficial strategy, especially in the general population aged above 70 years. [less ▲]

Detailed reference viewed: 5 (2 ULg)
Full Text
See detailConstruire un système de reconnaissance de l'économie sociale en Wallonie. Analyse des résultats issus des ateliers scénarios menés dans le cadre du projet SECOIA
Stassart, Isalyne ULg; Erpicum, Martin ULg; Fallon, Catherine ULg et al

Report (2017)

Quelles sont les pratiques communes aux entreprises d’économie sociale ? Quelles sont les dimensions qui pourraient les distinguer des autres entreprises dites capitalistiques ? Les membres actifs de ... [more ▼]

Quelles sont les pratiques communes aux entreprises d’économie sociale ? Quelles sont les dimensions qui pourraient les distinguer des autres entreprises dites capitalistiques ? Les membres actifs de l’économie sociale peuvent-ils proposer un ou plusieurs systèmes de reconnaissance de leurs spécificités ? Et sur base de quels indicateurs ? Tel était l’objet du troisième volet du projet SECOIA (projet de 22 mois commandité par la Région wallonne) qui visait à élaborer de manière participative et itérative un ou plusieurs système(s) de reconnaissance des entreprises de l’économie sociale. L’analyse de trois ateliers scénarios menés en décembre et février dernier avec 32 participants représentant les petites, moyennes et grandes entreprises de l’économie sociale en Région wallonne met en évidence une dimension transversale, et six dimensions spécifiques propres à l’économie sociale. [less ▲]

Detailed reference viewed: 32 (7 ULg)
Full Text
Peer Reviewed
See detailNutrition and physical activity in the prevention and treatment of sarcopenia: systematic review.
Beaudart, Charlotte ULg; Dawson, A.; Shaw, S. C. et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2017), 28(6), 1817-33

This systematic review summarizes the effect of combined exercise and nutrition intervention on muscle mass and muscle function. A total of 37 RCTs were identified. Results indicate that physical exercise ... [more ▼]

This systematic review summarizes the effect of combined exercise and nutrition intervention on muscle mass and muscle function. A total of 37 RCTs were identified. Results indicate that physical exercise has a positive impact on muscle mass and muscle function in subjects aged 65 years and older. However, any interactive effect of dietary supplementation appears to be limited. INTRODUCTION: In 2013, Denison et al. conducted a systematic review including 17 randomized controlled trials (RCTs) to explore the effect of combined exercise and nutrition intervention to improve muscle mass, muscle strength, or physical performance in older people. They concluded that further studies were needed to provide evidence upon which public health and clinical recommendations could be based. The purpose of the present work was to update the prior systematic review and include studies published up to October 2015. METHODS: Using the electronic databases MEDLINE and EMBASE, we identified RCTs which assessed the combined effect of exercise training and nutritional supplementation on muscle strength, muscle mass, or physical performance in subjects aged 60 years and over. Study selection and data extraction were performed by two independent reviewers. RESULTS: The search strategy identified 21 additional RCTs giving a total of 37 RCTs. Studies were heterogeneous in terms of protocols for physical exercise and dietary supplementation (proteins, essential amino acids, creatine, beta-hydroxy-beta-methylbuthyrate, vitamin D, multi-nutrients, or other). In 79% of the studies (27/34 RCTs), muscle mass increased with exercise but an additional effect of nutrition was only found in 8 RCTs (23.5%). Muscle strength increased in 82.8% of the studies (29/35 RCTs) following exercise intervention, and dietary supplementation showed additional benefits in only a small number of studies (8/35 RCTS, 22.8%). Finally, the majority of studies showed an increase of physical performance following exercise intervention (26/28 RCTs, 92.8%) but interaction with nutrition supplementation was only found in 14.3% of these studies (4/28 RCTs). CONCLUSION: Physical exercise has a positive impact on muscle mass and muscle function in healthy subjects aged 60 years and older. The biggest effect of exercise intervention, of any type, has been seen on physical performance (gait speed, chair rising test, balance, SPPB test, etc.). We observed huge variations in regard to the dietary supplementation protocols. Based on the included studies, mainly performed on well-nourished subjects, the interactive effect of dietary supplementation on muscle function appears limited. [less ▲]

Detailed reference viewed: 25 (11 ULg)
Full Text
Peer Reviewed
See detailManagement of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS and SIOG.
HADJI, P.; AAPRO, M.S.; BODY, J.J. et al

in Journal of Bone Oncology (2017), 23(7), 1-12

Background: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently ... [more ▼]

Background: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL). Patients and methods: A systematic literature review identified recent advances in the management of AIBL. Results with individual agents were assessed based on trial design, size, follow-up, and safety. Results: Several fracture related risk factors in patients with EBC were identified. Although, the FRAX algorithm includes fracture risk factors (RF) in addition to BMD, it does not seem to adequately address the effects of AIBL. Several antiresorptive agents can prevent and treat AIBL. However, concerns regarding compliance and longterm safety remain. Overall, the evidence for fracture prevention is strongest for denosumab 60 mg s.c. every 6 months. Additionally, recent studies as well as an individual patient data meta-analysis of all available randomized trial data support additional anticancer benefits from adjuvant bisphosphonate treatment in postmenopausal women with a 34% relative risk reduction in bone metastasis and 17% relative risk decrease in breast cancer mortality that needs to be taken into account when advising on management of AIBL. Conclusions: In all patients initiating AI treatment, fracture risk should be assessed and recommendation with regard to exercise and calcium/vitamin D supplementation given. Bone-directed therapy should be given to all patients with a T-score<−2.0 or with a T-score of<–1.5 SD with one additional RF, or with ≥2 risk factors (without BMD) for the duration of AI treatment. Patients with T-score>−1.5 SD and no risk factors should be managed based on BMD loss during the first year and the local guidelines for postmenopausal osteoporosis. Compliance should be regularly assessed as well as BMD on treatment after 12 - 24 months. Furthermore, because of the decreased incidence of bone recurrence and breast cancer specific mortality, adjuvant bisphosphonates are recommended for all postmenopausal women at significant risk of disease recurrence. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailAbaloparatide-SC for postmenopausal osteoporosis: analysis of the number needed to treat compared with teriparatide.
Reginster, Jean-Yves ULg; Black, D.M.; Hattersley, G. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritis increases the risk of cardiovascular disease: data from the osteoarthritis initiative.
Veronese, N.; Smith, T; Reginster, Jean-Yves ULg et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 15 (2 ULg)
See detailLe crédit hypothécaire au consommateur : Etat de la question
Biquet, Christine ULg; Beguin, Etienne

Book published by Larcier (2017)

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailLow bone mineral density and fractures are associated with incident cardiovascular disease: a systematic review and meta-analysis.
Veronese, N.; Stubbs, B.; Crepaldi, G. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 29 (2 ULg)
Full Text
See detailLa conclusion du contrat de crédit
Biquet, Christine ULg

in Biquet, Christine; Beguin, Etienne (Eds.) Le crédit hypothécaire au consommateur- Etat de la question (2017)

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailSarcopenia in nursing home residents: the senior cohort.
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Beaudart, Charlotte ULg et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 21 (3 ULg)
Full Text
Peer Reviewed
See detailPublic health and economic impact of vitamin D-fortified dairy products for fracture prevention in France.
Hiligsmann, M.; Burlet, N.; Fardellone, P. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 20 (2 ULg)
Full Text
Peer Reviewed
See detailSubjective sleep quality in sarcopenic vs non-sarcopenic older adults from the sarcophage cohort.
Locquet, Médéa ULg; Beaudart, Charlotte ULg; Delandsheere, Laura ULg et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailThe risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
Kendler, D.L.; Chines, A.; Brandi, M.L. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 26 (2 ULg)
Full Text
See detailLa défaillance du consommateur
Renson, Florence ULg; Biquet, Christine ULg

in Biquet, Christine; Beguin, Etienne (Eds.) Le crédit hypothécaire au consommateur : Etat de la question. (2017)

Detailed reference viewed: 18 (3 ULg)
Full Text
See detailLe capital et les intérêts
Biquet, Christine ULg

in Biquet, Christine; Beguin, Etienne (Eds.) Le crédit hypothécaire au consommateur : Etat de la question. (2017)

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailUltrasonic spray pyrolysis as a processing route for templated electrochromic tungsten oxide films
Chatzikyriakou, Dafni ULg; Maho, Anthony ULg; Cloots, Rudi ULg et al

in Microporous and Mesoporous Materials (2017), 240

Detailed reference viewed: 27 (10 ULg)